Binding ability of arginine, citrulline, N-acetyl citrulline and thiocitrulline with SARS COV-2 main protease using molecular docking studies
Abstract In this article, the binding abilities of arginine, citrulline, N-acetyl citrulline and thiocitrulline on the active sites of SARS-COV-2 protease have been investigated using in-silico studies. All the above ligands bind selectively and preferentially to Cys-145 active site and also to other amino acids surrounding to it in the main protease. Of which arginine forms less number of weaker bonds compared to the other ligands, it by itself is a precursor for the formation of citrulline analogues with in the cell. Major advantage of using the above ligands is that in addition to its preferential binding, they have the ability to increase the immunity by assisting NO generation. Our results show that N-acetyl citrulline, citrulline, thiocitrulline and arginine may be used as a supplement during the treatment of SARS-COV-2..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Network modeling analysis in health informatics and bioinformatics - 10(2021), 1 vom: 06. Apr. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Thimmasandra Narayan, Ramesh [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Citrulline analogues |
Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2021 |
---|
doi: |
10.1007/s13721-021-00301-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR043707971 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR043707971 | ||
003 | DE-627 | ||
005 | 20230519072444.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210407s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s13721-021-00301-x |2 doi | |
035 | |a (DE-627)SPR043707971 | ||
035 | |a (SPR)s13721-021-00301-x-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 004 |a 610 |a 570 |q ASE |
084 | |a 44.32 |2 bkl | ||
100 | 1 | |a Thimmasandra Narayan, Ramesh |e verfasserin |4 aut | |
245 | 1 | 0 | |a Binding ability of arginine, citrulline, N-acetyl citrulline and thiocitrulline with SARS COV-2 main protease using molecular docking studies |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2021 | ||
520 | |a Abstract In this article, the binding abilities of arginine, citrulline, N-acetyl citrulline and thiocitrulline on the active sites of SARS-COV-2 protease have been investigated using in-silico studies. All the above ligands bind selectively and preferentially to Cys-145 active site and also to other amino acids surrounding to it in the main protease. Of which arginine forms less number of weaker bonds compared to the other ligands, it by itself is a precursor for the formation of citrulline analogues with in the cell. Major advantage of using the above ligands is that in addition to its preferential binding, they have the ability to increase the immunity by assisting NO generation. Our results show that N-acetyl citrulline, citrulline, thiocitrulline and arginine may be used as a supplement during the treatment of SARS-COV-2. | ||
650 | 4 | |a SARS-COV-2 main protease |7 (dpeaa)DE-He213 | |
650 | 4 | |a Citrulline analogues |7 (dpeaa)DE-He213 | |
650 | 4 | |a Nitric oxide |7 (dpeaa)DE-He213 | |
650 | 4 | |a Immunity |7 (dpeaa)DE-He213 | |
773 | 0 | 8 | |i Enthalten in |t Network modeling analysis in health informatics and bioinformatics |d Wien : Springer, 2012 |g 10(2021), 1 vom: 06. Apr. |w (DE-627)SPR032186428 |w (DE-600)2649488-7 |x 2192-6670 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2021 |g number:1 |g day:06 |g month:04 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13721-021-00301-x |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.32 |q ASE |
951 | |a AR | ||
952 | |d 10 |j 2021 |e 1 |b 06 |c 04 |